Valuation: Grifols SA

Market Cap 6.54B 7.3B 6.01B 5.45B 10.18B 693B 10.37B 71.69B 28.78B 365B 27.39B 26.81B 1,150B P/E 2026 *
13.8x
P/E 2027 * 10.8x
Enterprise Value 14.76B 16.48B 13.58B 12.3B 22.99B 1,565B 23.42B 162B 64.99B 823B 61.85B 60.53B 2,596B EV / Sales 2026 *
1.92x
EV / Sales 2027 * 1.79x
Free-Float
79.65%
Yield 2026 *
2.51%
Yield 2027 * 2.7%
Manager TitleAgeSince
Chief Executive Officer 58 2024-03-31
Director of Finance/CFO 49 2024-09-15
Compliance Officer 54 2013-12-31
Director TitleAgeSince
Chairman 76 2010-01-24
Director/Board Member 70 2000-04-12
Director/Board Member 62 2015-05-23
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +2.08%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 7.67B 8.56B 7.06B 6.39B 11.95B 813B 12.17B 84.14B 33.78B 428B 32.14B 31.46B 1,349B 8.17B 9.12B 7.51B 6.81B 12.72B 866B 12.96B 89.58B 35.96B 455B 34.22B 33.49B 1,436B
Net income 534M 596M 491M 445M 832M 56.64B 848M 5.86B 2.35B 29.79B 2.24B 2.19B 93.96B 705M 787M 648M 587M 1.1B 74.71B 1.12B 7.73B 3.1B 39.3B 2.95B 2.89B 124B
Net Debt 8.22B 9.18B 7.56B 6.85B 12.81B 872B 13.05B 90.2B 36.21B 459B 34.46B 33.73B 1,446B 8.08B 9.03B 7.44B 6.74B 12.59B 857B 12.83B 88.68B 35.6B 451B 33.88B 33.16B 1,422B
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Grifols SA